Clinical Trial Update: Long-Term Evaluation of BIIB067 (Tofersen) [Phase 3]

View source ↗

Summary

Long-term evaluation results for tofersen (BIIB067) in amyotrophic lateral sclerosis due to SOD1 mutation have been posted from a Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Tofersen (tofersen)

Snippet

Sponsor: Biogen | Conditions: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Phase 3 | Status: COMPLETED | Results posted: 2025-08-29